(19)

(11)

EP 4 525 878 A1

(12)

(43) Date of publication: 26.03.2025 Bulletin 2025/13 (21) Application number: 23808571.6 (22) Date of filing: 18.05.2023

(51) International Patent Classification (IPC):  A61K 31/5415(2006.01) A61K 31/4196(2006.01) A61K 47/69(2017.01) A61P 29/00(2006.01) A61K 9/00(2006.01) A61K 47/02(2006.01) A61P 25/06(2006.01) (52) Cooperative Patent Classification (CPC): A61K 31/5415; A61K 31/4196; A61K 9/0007; A61K 9/2009; A61K 9/205; A61K 9/209; A61K 31/4439; A61K 31/724; A61K 47/6951; A61P 25/00; C08B 37/0015 (86) International application number: PCT/US2023/067172 (87) International publication number: WO 2023/225596 (23.11.2023 Gazette 2023/47)

(84) Designated Contracting States: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR Designated Extension States: BA Designated Validation States: KH MA MD TN (30) Priority: 19.05.2022 US 202263343982 P (71) Applicant: Axsome Therapeutics, Inc. New York, NY 10007 (US)	(72) Inventor: TABUTEAU, Herriot New York, New York 10007 (US) (74) Representative: Murgitroyd & Company  165-169 Scotland Street Glasgow G5 8PL Glasgow G5 8PL (GB)